Stewart Dolin took six generic Paxil (paroxetine) tablets in the days before he took his own life in 2010. According to a lawsuit filed by his widow, the small number of prescription meds triggered Stewart’s suicide rather than treat his anxiety.
“If you ask anyone who knew him, he was laid back, high on life, so there was this unbelievable disconnect between how he lived his life: a beautiful man, a beautiful life. The tragedy and violence of his death … it was, it just didn’t make sense,” said Wendy Dolin of her late husband, during an interview with NBC News Chicago on May 28, 2014.
“I Googled ‘akathisia and Paxil’ and it was like, bone chilling … if this can happen to someone like Stewart, I don’t think anyone is immune,” Dolin said.
The lawsuit, now in federal court in Chicago, claims that the warning label on the bottle of generic Paxil that Stewart Dolin was taking did not include the risk of increased suicidality for adults over the age of 24. Furthermore, the lawsuit claims that GlaxoSmithKline (GSK), the manufacturer of Paxil, knew of the increased risk and suppressed this information from the public.
GSK Depositions Played at Dolin Paxil Suicide Trial
The trial of Dolin v. Smithkline Beecham Corp. (D/B/A GlaxoSmithKline-GSK) began on March 14, 2017 in Chicago, Illinois over the alleged paroxetine-induced wrongful death of Wendy Dolin’s late husband, Stewart Dolin. Mr. Dolin was a partner at the law firm Reed Smith.
On July 10, 2010, Dolin began taking the prescription antidepressant medication paroxetine. The brand name version of this medication is called Paxil which was researched, developed, manufactured and marketed by GlaxoSmithKline (“GSK”). People use the term Paxil to refer to brand name Paxil and, sometimes, to generic paroxetine. Generic and name brand Paxil are the same chemical compound and both use the same product information labeling. GSK created and was responsible for maintaining the accuracy of the Paxil label.
The following depositions have been taken from GSK executives relating to Paxil suicide cases. In the first video, former GSK CEO Jean-Pierre Garnier says in his testimony that GSK’s way of counting suicidal behavior events in GSK’s Paxil clinical trials was incorrect.
In the next deposition, GlaxoSmithKline biostatistician John Davies is questioned about GSK’s improperly counting suicidal behavior and its effect on calculating suicide risk rates during Paxil clinical trials.
Lastly, former GlaxoSmithKline executive Dr. Geoffrey Dunbar says in his testimony that he helped author the drafts of the Paxil suicide report that the U.S. Food and Drug Administration (FDA) asked for in 1991. The calculations in this report showed and suggested that instead of Paxil increasing the suicide risk by nearly 9 times, the drug decreased suicidal behavior. He admits in his deposition that his reports include improperly counted suicidal behavior events and that publications in which he participated writing had incorrectly conveyed Paxil reduced suicidal behavior.